I
 
 





ntroduction:Long term vascular access has become more important as patients live longer on dialysis. Improved survival on hemodialysis has resulted in an increasing number of patients with failed vascular access, so an increasing number of options for vascular access have to be added to the surgeon’s armamentarium. In a number of patients, basilic vein transposition is an often overlooked means of arteriovenous access that has a superior patency compared with bridge fistulas using polytetrafluoroethylene (PTFE). And this brought vascular surgeons of Imam-Reza hospital to use this technique in patients with complications in normal fistulas. This article evaluates the survival rate of these fistulas and compares them with patency rates reported worldwide.
Materials and Methods: This study was conducted on, 25 End Stage Renal Disease (ESRD) patients, undergone superficial basilic vein transposition from 2002 till 2005. In these patients, superficial basilic vein transposition method was performed for an arteriovenous fistula (AVF). Demographic data were collected using medical records, and then patients were examined clinically. Patency rate was evaluated using life tables by SPSS version 13 and compared with similar results reported worldwide.
Results: Overall 70.8% were male patients and 29.2% were female. Hypertension was seen in 87.5% of cases and 37.5% suffered from diabetes. Seventy four percent of our cases underwent basilic vein transposition after a failing AVF, one case after a rejected transplant and one after a failed graft. The longest patency rate was 30 months and the shortest was 4 months. The patency rate for the first 6 months was 86% and after one year 77% and after 26 months 58%.
Conclusion: The one year patency rate reported for fistulas by basilica vein transposition method is 90-60% which justifies the results of this article (62.5%). these results suggest that this method can be used as a new access line for dialyzing ESRD patients before using graft fistulas.